Loading clinical trials...
Loading clinical trials...
The HIt HArd and hiT Early in Multiple Sclerosis Trial - HiHat Trial A Phase 2 Study of Sequential Treatment With Rituximab and Cladribine for Relapsing-remitting Multiple Sclerosis
Conditions
Interventions
Sequential treatment with rituximab and cladribine
Locations
4
Sweden
Falu Lasarett, Neurologen
Falun, Sweden
Gävle sjukhus, Neurologmottagningen
Gävle, Sweden
Centralsjukhuset Karlstad, Neurologi och Rehabiliteringskliniken
Karlstad, Sweden
Uppsala University Hospital
Uppsala, Sweden
Start Date
April 15, 2026
Primary Completion Date
December 31, 2030
Completion Date
December 31, 2030
Last Updated
April 8, 2026
NCT05758831
NCT06586177
NCT05906992
NCT05755061
NCT01805336
NCT04940065
Lead Sponsor
Uppsala University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions